Pyxis Oncology Announces New Inducement Grants in Compliance with Nasdaq Rules

BOSTON, Dec. 29, 2023 - Pyxis Oncology, Inc. PYXS, a clinical-stage biotech firm specializing in the development of innovative therapeutics to combat challenging cancers, has announced the recent approval of inducement grants by the Compensation Committee of its Board of Directors. This move has been made in accordance with Nasdaq Listing Rule 5635(c)(4), which relates to equity awards granted to new employees as an inducement to join a company.

Pyxis Oncology's Dedication to Next-Generation Cancer Treatments

With its headquarters nestled in the hub of biotechnology innovation in Cambridge, Massachusetts, Pyxis Oncology is pioneering progress in the medical fight against cancer. The company's focus is sharply aimed at developing next-generation antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies, targeting those cancers that currently elude effective treatments. Through its relentless research and development, Pyxis Oncology aspires to bring hope and solutions to individuals battling these tough diseases.

Commitment to Transparent and Equitable Employee Incentives

The approval of inducement grants underscores Pyxis Oncology's commitment to not only attract exceptional talent but also to ensure transparent and equitable compensation for its team members. These types of inducement grants are a strategic tool used by public companies, particularly in the biotechnology sector, to incentivize and secure highly skilled professionals who are essential to achieving research breakthroughs and commercial success.

Ensuring Compliance with Nasdaq Listing Rules

In the pursuit of corporate governance excellence, Pyxis Oncology diligently adheres to the Nasdaq Listing Rules. The inducement grants in question are being reported in compliance with Rule 5635(c)(4), reflecting the organization's transparent dealings and its high standards of accountability towards its shareholders and the wider market.

Pyxis, Oncology, Inducement, Grants, Nasdaq, Cancer, Therapeutics, Biotech, ADC, mAb, Cambridge, Innovation, Research, Governance, Compliance